Kuros Biosciences (Formally known as Cytos Biotech; Merged with Kuros Biosurgery)
Wagistrasse 25
Postfach
Zurich-Schlieren
8952
Tel: 41-1-733-47-47
Fax: 41-1-733-47-40
Website: http://www.cytos.com/
Email: info@cytos.com
37 articles about Kuros Biosciences (Formally known as Cytos Biotech; Merged with Kuros Biosurgery)
-
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences
7/15/2021
XOMA Corporation, announced it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod, an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones.
-
Clinical Catch-Up: September 2-8
9/9/2019
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. -
Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand
7/9/2019
Kuros Biosciences announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group, a leading provider of medical equipment, devices and consumables.
-
Biotech Movers and Shakers Aug. 27
8/27/2018
Who made a splash in the biotech world this week? Here are some notable people. -
Kuros Biosciences Appoints Chief Medical Officer
3/8/2016
-
Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which Is Renamed Kuros Biosciences
1/20/2016
-
LSP’s Portfolio Company Kuros Biosciences Closes Merger With Cytos And Is Now Listed As Kuros Biosciences Ltd On Swiss Stock Exchange
1/19/2016
-
Cytos Biotechnology Ltd. Will Be Renamed Kuros Biosciences , Constitutes Its Board Of Directors And Appoints Executive Officers
1/8/2016
-
VC-Backed Kuros Biosurgery Merges with Cytos Biotech
12/3/2015
-
Cytos Biotechnology AG's Asthma Drug CYT003 Flunks Pivotal Phase 2b Study
4/14/2014
-
Cytos Biotechnology AG Rights Offering Oversubscribed - CHF 24.3 Million Raised
11/18/2013
-
Cytos Biotechnology AG to Host Investor and Analyst R&D Day in New York City
10/17/2013
-
Cytos Biotechnology AG Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
9/9/2013
-
Cytos Biotechnology AG Reports Second Quarter 2013 Financial Results and Recent Developments
8/6/2013
-
A*STAR and Cytos Biotechnology AG Bring Singapore's First Influenza Vaccine to Clinical Testing
5/17/2013
-
Cytos Biotechnology AG Reports First Quarter 2013 Financial Results and Recent Development
4/25/2013
-
The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology AG’s CYT003 for the Treatment of Allergic Asthma
3/13/2013
-
Cytos Biotechnology AG VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
2/4/2013
-
Cytos Biotechnology AG Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
11/6/2012
-
Cytos Biotechnology AG Appoints Dr. Christian Itin as Chief Executive Officer
10/9/2012